Quercetin 500 mg daily × Improved clinical liver outcomes — Evidence Check

Required evidence, verification status and materials actually read
Item	AVerification status	BReading scope	CReview item	DCurrent findings	EWhy unverified	FRequired materials and conditions	GFurther research
1	Partly verified	Full text not readStored summary read	N01 · Evidence conditionSelected clinical liver outcome and original valuesRequired	Preserve the existing ? grade for improved clinical liver outcomes and the note that cirrhosis, hospitalization and death were not tested. Parent C54 and the positive MRI result belong to the separate original assessment context. S01	Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. The subclaim has no score, status or assessment axes; do not fill them with parent values. Do not create clinical benefit, a null effect, a grade or independent certification. Content review remains incomplete.	Existing question, grade and note; parent context and absent fields	Connect the original question to additional materials in proposed update research; no new investigation, calculation or trial is performed now.
2	Unverified	Full text not readStored summary read	N02 · Evidence conditionClinical outcomes: definitions and measurementRequired	The original note states that this trial did not test cirrhosis, hospitalization or death. Distinguish MRI liver fat and liver enzymes from actual disease outcomes. S01	Information currently needed is unverified in the preserved summary. Definitions, adjudication/verification, events/denominators, timing and data linkage for direct clinical endpoints are unverified. Untested outcomes must not become zero events or zero effect. Content review remains incomplete.	Definitions and adjudication of original outcomes such as cirrhosis, hospitalization and death	Proposed research distinguishing imaging/laboratory measures from clinical outcomes; no new investigation, calculation or trial is performed now.
3	Partly verified	Full text not readStored summary read	N03 · Evidence conditionParticipants, disease and risk scopeRequired	The current direct bibliography concerns an MRI crossover trial in 41 people with nonalcoholic fatty liver disease. Do not transfer them into a verified direct population for the selected clinical outcome. S01	Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Clinical disease stage, baseline risk, eligibility, populations by group and clinical-event denominators/missingness are unverified. Do not transfer an effect to every liver disease or population. Content review remains incomplete.	Original MRI participants and the population analyzed for clinical outcomes	Proposed research on disease/population and the applicability of clinical effects; no new investigation, calculation or trial is performed now.
4	Unverified	Full text not readStored summary read	N04 · Evidence conditionQuercetin and direct clinical interventionRequired	500 mg/day, 12 weeks and placebo crossover are exposure/comparison conditions of the original MRI trial. Do not describe them as a dose or method with verified clinical liver benefit. S01	Information currently needed is unverified in the preserved summary. Product/composition, dose/duration, intervention/control, actual exposure, adherence and subsequent treatment in direct clinical trials are unverified. Do not create new dosing or treatment guidance. Content review remains incomplete.	Formulation, dose, strategy and actual clinical comparison	Proposed research on formulation/strategy and attribution to the clinical question; no new investigation, calculation or trial is performed now.
5	Partly verified	Full text not readStored summary read	N05 · Evidence conditionDirect bibliography, registration and report relationshipsRequired	The existing evidence and citation lists contain only the Li 2024 MRI trial. This preserved review summary links no direct report of clinical cirrhosis, hospitalization or death. S01	Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Direct clinical originals, trial/registration, plans/follow-up material, identity and scope are unverified or unread. Do not invent reports/URLs or new external reading. Content review remains incomplete.	Direct original reports, registration and correspondence for the selected clinical question	Proposed research linking the original text/assessment with direct reports; no new investigation, calculation or trial is performed now.
6	Partly verified	Full text not readStored summary read	N06 · Evidence conditionOriginal MRI values and clinical effectsRequired	MRI 11.5%±6.4→9.6%±5.8, placebo change −0.1%±2.6, P=.013 and adjusted P=.028 are MRI results. They are not estimates for cirrhosis, hospitalization or death. S01	Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Imaging/disease correspondence by person and timepoint and direct clinical material are unverified. Do not calculate clinical events, effects or CIs from MRI changes. Content review remains incomplete.	Surrogate comparisons/timing and their relationship to clinical outcomes	Proposed research distinguishing surrogate results from actual disease outcomes; no new investigation, calculation or trial is performed now.
7	Unverified	Full text not readStored summary read	N07 · Evidence conditionBetween-group clinical effects, CIs and thresholdsRequired	The original positive MRI result, absent CI in the abstract/public table and undeclared minimum MRI threshold are not verified values or an analysis specification for a clinical effect. S01	Information currently needed is unverified in the preserved summary. Clinical-event values by group, effects/CIs/P values, models, prespecified important differences and power are unverified. Do not create a treatment effect, null effect, CI or threshold. Content review remains incomplete.	Direct clinical effect/precision and prespecified important difference	Proposed research distinguishing clinical uncertainty from clinical meaning; no new investigation, calculation or trial is performed now.
8	Unverified	Full text not readStored summary read	N08 · Evidence conditionClinical timing and long-term follow-upRequired	The 12-week MRI period and crossover after a four-week washout are not a verified assessment period for clinical cirrhosis, hospitalization or death. S01	Information currently needed is unverified in the preserved summary. Assessment windows, occurrence/recurrence, long-term follow-up/censoring, discontinuation/death and competing events for direct clinical outcomes are unverified. Do not newly calculate total duration or event totals. Content review remains incomplete.	Specifications for event occurrence, exposure, follow-up and censoring	Proposed follow-up research distinguishing duration from disease outcomes; no new investigation, calculation or trial is performed now.
9	Unverified	Full text not readStored summary read	N09 · Evidence conditionClinical participants/events, denominators and missingnessRequired	41 randomized and 36 completed are data from the MRI crossover trial. S01	Information currently needed is unverified in the preserved summary. Groups/denominators, people/recurrent events, exclusion, missingness, withdrawal/censoring, analysis and missing-data models for each direct clinical endpoint are unverified. Do not automatically reuse MRI denominators. Content review remains incomplete.	Randomized, observed and analyzed units and clinical-event units	Proposed research on population/event units and missing-data assumptions; no new investigation, calculation or trial is performed now.
10	Unverified	Full text not readStored summary read	N10 · Evidence conditionOriginal allocation/blinding and clinical adjudicationRequired	The original double-blind MRI crossover design description belongs to the parent trial context. S01	Information currently needed is unverified in the preserved summary. Direct allocation units/sequences, generation/concealment, clinical adjudication/analysis blinding, measurement and models for clinical effects are unverified. Do not inherit original B1 or ITT as a new clinical review. Content review remains incomplete.	Allocation, measurement and analysis procedures in direct clinical trials	Proposed research on procedures and clinically observed outcomes; no new investigation, calculation or trial is performed now.
11	Unverified	Full text not readStored summary read	N11 · Evidence conditionClinical registration and prespecified plansRequired	ChiCTR2100047904 and the primary MRI endpoint description are the preserved identity and plan of the original MRI trial. Do not promote clinical endpoints to prespecified, verified outcomes. S01	Information currently needed is unverified in the preserved summary. Original clinical plans/registration history, endpoint hierarchy/multiplicity, SAP, follow-up/changes and report correspondence are unread. Content review remains incomplete.	Registration/hierarchy, analysis and changes for the selected clinical endpoint	Proposed research linking prespecified plans with clinical reports; no new investigation, calculation or trial is performed now.
12	Partly verified	Full text not readStored summary read	N12 · Evidence conditionWeight mediation and direct liver effectsRequired	Preserve the original weight description: −1.5±2.6 kg versus −0.2±1.8 kg, correlation with MRI reduction and an unseparated direct liver effect. Do not present direct or mediated effects on clinical disease as verified. S01	Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Clinical-event correspondence, timing, causal/mediation models and concurrent activity/diet/treatment are unverified. Do not calculate new clinical effects from weight or MRI. Content review remains incomplete.	Weight/exposure and original MRI/clinical outcomes	Proposed research distinguishing exposure/mediation from actual clinical attribution; no new investigation, calculation or trial is performed now.
13	Partly verified	Full text not readStored summary read	N13 · Evidence conditionLiver enzymes, nonsignificant secondary outcomes and clinical outcomesRequired	The original description says other secondary endpoints, including liver enzymes, were nonsignificant. Do not transfer this into verified clinical null effects, an effect of zero or confirmation of MRI benefit. S01	Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Plans/timepoints, values/denominators/CIs/models for each measure and correspondence with clinical disease events are unverified. Content review remains incomplete.	Definitions and results for other measures and disease outcomes	Proposed research on measure/disease differences and uncertainty; no new investigation, calculation or trial is performed now.
14	Unverified	Full text not readStored summary read	N14 · Evidence conditionSubsequent exposure and clinical attributionRequired	Retain the original quercetin/placebo trial context. S01	Information currently needed is unverified in the preserved summary. Diet/activity/weight management, drugs/tests/treatment, products, individual exposure/adherence and subsequent course for clinical disease are unverified. Do not create treatment, weight-management or product guidance. Content review remains incomplete.	Actual concurrent exposure/treatment and individual course/events	Proposed research on concurrent exposures and attribution of clinical outcomes; no new investigation, calculation or trial is performed now.
15	Partly verified	Full text not readStored summary read	N15 · Evidence conditionFunding/products and scope of originalsRequired	The unidentified funding name in public text, undisclosed manufacturer funding/products/analysis, institutional affiliations and no-COI statement are historical descriptions of the original MRI trial. S01	Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Full disclosures of funding/products, analysis/writing/publication, company/employee authors, contributions and COI in direct clinical trials are unread. Do not fill absent support or current independence from the original declaration. Content review remains incomplete.	Original trial support disclosures versus direct clinical material	Proposed research on support/declarations and actual direct material; no new investigation, calculation or trial is performed now.
16	Unverified	Full text not readStored summary read	N16 · Harm-information gaps supplementing the efficacy tableClinical harm and safety materialSupplementary	The original MRI trial description of unreported significant safety-metric differences or related adverse events, 41 participants and limits for rare harms belongs to the parent context. S01	Information currently needed is unverified in the preserved summary. Harm denominators/events, discontinuation/relatedness, collection/missingness and long-term/vulnerable populations for the clinical population/period are unverified. Do not turn nonreporting into zero harm or treatment safety. Content review remains incomplete.	Definitions, collection and follow-up of harms in direct clinical treatment	Proposed research on efficacy and actually observed harms by population; no new investigation, calculation or trial is performed now.
17	Partly verified	Full text not readStored summary read	N17 · Evidence conditionSame trial/periods and clinical replicationRequired	Do not count crossover periods/the same people, MRI/weight/liver enzymes, timepoints or sibling sheets from the sole Li 2024 MRI report as new independent trials or participants. Do not invent long-term clinical follow-up reports. S01	Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Direct clinical trials/bibliography/registration, unique participants/events, follow-up relationships and independent replication are unverified. Do not inherit original R1/I2 as clinical replication certification. Content review remains incomplete.	Relationships among reports/trials/participants/periods and selected clinical material	Proposed research distinguishing the same material from separate clinical replication; no new investigation, calculation or trial is performed now.
18	Partly verified	Full text not readStored summary read	N18 · Evidence conditionGeneralization across disease, products and durationRequired	The specific 500 mg/12-week MRI result does not support every polyphenol or improvement in cirrhosis, hospitalization or death. S01	Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Direct material for other formulations/doses, disease stages/populations and long-term effects/harms is unverified. Do not create new drug, intake or treatment methods. Content review remains incomplete.	The selected clinical question versus other populations, exposures and durations	Proposed research on the selected question and other conditions; no new investigation, calculation or trial is performed now.
19	Partly verified	Full text not readStored summary read	N19 · Evidence conditionOriginal subclaim ? grade, parent C54 and historyRequired	Preserve the subclaim ? grade and untested-outcome note, parent C54/Good, original assessment axes/Korean and English text, 2026-08-26 and empty correction/deliberation records in the full preserved summary. S01	Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Do not fill absent subclaim scores/status/axes or the parent’s unrecorded classification information. Do not promote historical cross-validation, abstract/public-table/paper descriptions into current clinical original reading, review or condition fulfillment. Content review remains incomplete.	Original subclaim values/absences, parent axes, Korean/English text, dates and corrections	Propose update research on source-material changes and production versions; no new investigation, calculation or trial is performed now.
20	Partly verified	Full text not readStored summary read	N20 · Evidence conditionSummary/bibliography and gaps in direct clinical materialRequired	Link the preserved summary with Li 2024/PMID 39032786 MRI bibliography/URL. They do not replace direct material or links for clinical disease outcomes. S01	Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Direct clinical material and the original MRI paper/registration/protocol/SAP/disclosures are unread; access was not attempted. Do not upgrade current acquisition/reading/review status using original links/identifiers; links/clicks are not checked. Content review remains incomplete.	Actual reading/URLs for each material and selected clinical material	Propose scoped update research based on materials actually acquired; no new investigation, calculation or trial is performed now.

No items match your search or filter.

20 itemsWhat the statuses mean

Assessment scope

Stored-material review date: Not recorded
Original evidence cut-off: 2026-08-26
Scope actually checked: Existing review summaries and stored records of methodological application. Full papers, supplements, registrations, plans and original data were not read.
What the dates mean: This is the date the stored materials were checked, not the date of a new search of the clinical literature.
Population: The current preserved summary concerns an MRI crossover trial in nonalcoholic fatty liver disease: 41 participants, 36 completed. Do not transfer them to verified populations/event denominators for clinical cirrhosis, hospitalization or death. Clinical disease stage, baseline risk, recruitment/group-specific analysis/observation and censoring/missingness remain unverified without direct material.
Ingredient, formulation and route: The direct intervention/comparison for the selected clinical outcome is unverified. Link only MRI exposure/comparison context from the original quercetin 500 mg/placebo crossover; do not present it as a dose or method with verified clinical benefit. Product/duration, actual exposure/adherence/concurrent treatment and subsequent strategies are unverified; no new intake or treatment guidance is created.
Dose: 12 weeks and crossover after a 4-week washout are MRI trial conditions, not verified treatment/assessment periods for clinical disease. Direct clinical exposure, dose/duration, long-term follow-up and discontinuation are unverified; no new duration/dose conversions are performed.
Comparator: The original double-blind MRI placebo crossover and reported ITT do not verify direct clinical disease allocation, comparison or analysis. Control, allocation/adjudication, concurrent management/treatment, models/missingness and actual units in clinical trials/endpoints are unverified.
Measured outcome: The selected existing ? grade/note records that this trial did not test cirrhosis, hospitalization or death. Definitions/adjudication, events/denominators, timing, between-group effects/CIs/P values, prespecified important differences and power for these clinical endpoints are unverified. MRI 11.5%±6.4→9.6%±5.8, placebo change −0.1%±2.6, P=.013, adjusted P=.028 and weight changes/correlation are other measures, not clinical estimates/effects. Do not turn untested outcomes into zero effects/events, safety certification or confirmed null effects.
Duration: Direct clinical disease follow-up/assessment windows, cumulative/recurrent events/hospitalization, censoring/death and follow-up material are unverified. Distinguish original 12-week MRI/crossover from long-term testing of cirrhosis, hospitalization or death. Do not invent follow-up reports/numbers.
Questions outside this scope: New effect/change/response-rate/CI calculations or arbitrary %/%p corrections from MRI baseline/final values, placebo change, original approximate −1.9 percentage points/P values/± quantities and sample sizes; Summing two crossover periods/the same participants as new independent trials/participants, or deriving hypothetical total duration/exposure from 12 weeks/4 weeks; Filling an ITT account with unverified observed denominators, imputation models or an all-completer population; Turning weight correlation and MRI benefit into confirmation of direct hepatic causation/separated mediation, or calculating new direct effects; Reusing MRI/liver-enzyme/other secondary outcomes as improved cirrhosis/hospitalization/death, or exactly zero clinical effects/equivalence; Inheriting historical CI/funding checking in abstracts/public tables/full text as current whole external-document reading/review; Turning undisclosed manufacturer support, institutional affiliations/no-COI declarations and original I2 into absence of each support item/current independence verification; Turning original safety non-reporting/nonsignificance and rare-harm limitations into zero harms or treatment-safety certification; Creating currently absent clinical original reports/registration/follow-up materials or invented citations/values; Inheriting parent scores/axes and historical cross-checking as subclaim scores/current review/external reading; New calculations, hypothetical values, effects/CIs, grades, independence certification or product-intake/diet/activity/testing/treatment implementation guidance

Evidence and sources

The links below lead to the sources. A link alone does not mean the original source was read or its latest publication status verified.

S01 · Li N et al. 2024

PubMed

Material type: Randomized double-blind placebo-controlled crossover trial
Materials actually read: Summary read; external material unread
Findings recorded in the stored summary: The preserved result of this report is the MRI surrogate 11.5%±6.4→9.6%±5.8 versus placebo change −0.1%±2.6; P=0.013, adjusted P=0.028. These are not effect values for the selected clinical cirrhosis, hospitalization or death outcomes. Preserve the existing ? grade/untested-outcome note and unverified direct clinical definitions, populations, events/denominators, duration/estimates/CIs and plans.
Record level: Outcome wording in the stored summary
Study overlap and independent replication: S01 Li 2024/ChiCTR2100047904 is a single double-blind placebo-controlled crossover trial in nonalcoholic fatty liver disease, with 41 randomized and 36 completed. Distinguish original quercetin 500 mg/day, 12-week intervention and crossover after a 4-week washout from unverified actual sequence/period/exposure and ITT/observation/missing-data models. Quercetin-period MRI 11.5%±6.4 to 9.6%±5.8, original approximate −1.9 percentage points, placebo change −0.1%±2.6, P=.013 and adjusted P=.028 are original surrogate results, not new calculations. Do not arbitrarily correct %/%p wording; retain gaps in the type of ± quantity, between-treatment CI/important difference and original period/within-person estimates. Weight changes −1.5±2.6 kg versus −0.2±1.8 kg, correlation with MRI reduction/unseparated direct hepatic effects, nonsignificant liver enzymes/other secondary outcomes and untested clinical cirrhosis/hospitalization/death are distinct outcomes. Do not sum the same participants/arms, crossover periods, MRI/weight/liver enzymes, citations or sibling sheets as new independent trials/participants. Do not create follow-up reports/clinical effects or inherit original R1/I2 and historical abstract/public-table/full-text checking accounts as current review/external reading. Report/material-slot counts are not unique clinical trial/participant/independent-replication totals; no new sums or independence certification are performed.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored summary	Stored file	Stored summary	Summary read	Only stored-summary and bibliographic content was used for production. External material verification/review is not complete.
External paper	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Registration material	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Protocol	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Statistical analysis plan	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Funding, product-support and COI material	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.

Report counts versus independent study counts

S01 Li 2024/ChiCTR2100047904 is a single double-blind placebo-controlled crossover trial in nonalcoholic fatty liver disease, with 41 randomized and 36 completed. Distinguish original quercetin 500 mg/day, 12-week intervention and crossover after a 4-week washout from unverified actual sequence/period/exposure and ITT/observation/missing-data models. Quercetin-period MRI 11.5%±6.4 to 9.6%±5.8, original approximate −1.9 percentage points, placebo change −0.1%±2.6, P=.013 and adjusted P=.028 are original surrogate results, not new calculations. Do not arbitrarily correct %/%p wording; retain gaps in the type of ± quantity, between-treatment CI/important difference and original period/within-person estimates. Weight changes −1.5±2.6 kg versus −0.2±1.8 kg, correlation with MRI reduction/unseparated direct hepatic effects, nonsignificant liver enzymes/other secondary outcomes and untested clinical cirrhosis/hospitalization/death are distinct outcomes. Do not sum the same participants/arms, crossover periods, MRI/weight/liver enzymes, citations or sibling sheets as new independent trials/participants. Do not create follow-up reports/clinical effects or inherit original R1/I2 and historical abstract/public-table/full-text checking accounts as current review/external reading. Report/material-slot counts are not unique clinical trial/participant/independent-replication totals; no new sums or independence certification are performed.

Review criteria

Version 1.0 · Criteria record date 2026-10-06. These are Chamgap's own application conditions, informed by the referenced methods. They do not constitute official assessment-tool certification or a new efficacy score.

N01 · Selected clinical liver outcome and original values

Required materials and conditions: Existing question, grade and note; parent context and absent fields
Conditions for verification: Existing question, grade and note; parent context and absent fields requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Preserve the existing ? grade/untested-outcome note for the selected clinical liver outcome and the current MRI report context. Retain gaps in direct cirrhosis/hospitalization/death material, definitions, effects, denominators and duration. Do not substitute MRI/weight/liver-enzyme measures, values, support or safety for direct clinical effects or create new intake/treatment guidance.
Why this condition is needed: Distinguish Existing question, grade and note; parent context and absent fields to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are custom design; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is custom design; M04 §4.5, §4.6.3; limits on current material conversion reflect the review scope and custom design

N02 · Clinical outcomes: definitions and measurement

Required materials and conditions: Definitions and adjudication of original outcomes such as cirrhosis, hospitalization and death
Conditions for verification: Definitions and adjudication of original outcomes such as cirrhosis, hospitalization and death requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Preserve the existing ? grade/untested-outcome note for the selected clinical liver outcome and the current MRI report context. Retain gaps in direct cirrhosis/hospitalization/death material, definitions, effects, denominators and duration. Do not substitute MRI/weight/liver-enzyme measures, values, support or safety for direct clinical effects or create new intake/treatment guidance.
Why this condition is needed: Distinguish Definitions and adjudication of original outcomes such as cirrhosis, hospitalization and death to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is custom design; M08 Table 8.2.a, M03 §3.2.4; custom application; M03 §3.2.4; custom extension boundary; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is custom design

N03 · Participants, disease and risk scope

Required materials and conditions: Original MRI participants and the population analyzed for clinical outcomes
Conditions for verification: Original MRI participants and the population analyzed for clinical outcomes requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Preserve the existing ? grade/untested-outcome note for the selected clinical liver outcome and the current MRI report context. Retain gaps in direct cirrhosis/hospitalization/death material, definitions, effects, denominators and duration. Do not substitute MRI/weight/liver-enzyme measures, values, support or safety for direct clinical effects or create new intake/treatment guidance.
Why this condition is needed: Distinguish Original MRI participants and the population analyzed for clinical outcomes to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: M03 §3.2.1; detailed population conditions are custom design; M03 §3.2.1–3.2.4; dose/duration/effect-modification details are custom design; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is custom design

N04 · Quercetin and direct clinical intervention

Required materials and conditions: Formulation, dose, strategy and actual clinical comparison
Conditions for verification: Formulation, dose, strategy and actual clinical comparison requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Preserve the existing ? grade/untested-outcome note for the selected clinical liver outcome and the current MRI report context. Retain gaps in direct cirrhosis/hospitalization/death material, definitions, effects, denominators and duration. Do not substitute MRI/weight/liver-enzyme measures, values, support or safety for direct clinical effects or create new intake/treatment guidance.
Why this condition is needed: Distinguish Formulation, dose, strategy and actual clinical comparison to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labels and checking adaptations are internally designed; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application; M03 §3.2.1–3.2.4; dose, duration and effect-modification details are internally designed

N05 · Direct bibliography, registration and report relationships

Required materials and conditions: Direct original reports, registration and correspondence for the selected clinical question
Conditions for verification: Direct original reports, registration and correspondence for the selected clinical question requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Preserve the existing ? grade/untested-outcome note for the selected clinical liver outcome and the current MRI report context. Retain gaps in direct cirrhosis/hospitalization/death material, definitions, effects, denominators and duration. Do not substitute MRI/weight/liver-enzyme measures, values, support or safety for direct clinical effects or create new intake/treatment guidance.
Why this condition is needed: Distinguish Direct original reports, registration and correspondence for the selected clinical question to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: M04 §4.5–4.6 material-collection/selection principles; separation of access/reading and hyperlink conventions are custom design; M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linkage is a custom application; M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are custom design

N06 · Original MRI values and clinical effects

Required materials and conditions: Surrogate comparisons/timing and their relationship to clinical outcomes
Conditions for verification: Surrogate comparisons/timing and their relationship to clinical outcomes requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Preserve the existing ? grade/untested-outcome note for the selected clinical liver outcome and the current MRI report context. Retain gaps in direct cirrhosis/hospitalization/death material, definitions, effects, denominators and duration. Do not substitute MRI/weight/liver-enzyme measures, values, support or safety for direct clinical effects or create new intake/treatment guidance.
Why this condition is needed: Distinguish Surrogate comparisons/timing and their relationship to clinical outcomes to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: M03 §3.2.4; custom extension boundary; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is custom design; M04 §4.6.3, M15 §15.3.1–15.3.3; status separation is custom design; M15 §15.3.1–15.3.3; custom application

N07 · Between-group clinical effects, CIs and thresholds

Required materials and conditions: Direct clinical effect/precision and prespecified important difference
Conditions for verification: Direct clinical effect/precision and prespecified important difference requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Preserve the existing ? grade/untested-outcome note for the selected clinical liver outcome and the current MRI report context. Retain gaps in direct cirrhosis/hospitalization/death material, definitions, effects, denominators and duration. Do not substitute MRI/weight/liver-enzyme measures, values, support or safety for direct clinical effects or create new intake/treatment guidance.
Why this condition is needed: Distinguish Direct clinical effect/precision and prespecified important difference to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: M15 §15.3.1–15.3.3; custom application; M08 Table 8.2.a, M04 §4.6.3; custom application; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is custom design

N08 · Clinical timing and long-term follow-up

Required materials and conditions: Specifications for event occurrence, exposure, follow-up and censoring
Conditions for verification: Specifications for event occurrence, exposure, follow-up and censoring requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Preserve the existing ? grade/untested-outcome note for the selected clinical liver outcome and the current MRI report context. Retain gaps in direct cirrhosis/hospitalization/death material, definitions, effects, denominators and duration. Do not substitute MRI/weight/liver-enzyme measures, values, support or safety for direct clinical effects or create new intake/treatment guidance.
Why this condition is needed: Distinguish Specifications for event occurrence, exposure, follow-up and censoring to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is custom design; M03 §3.2.1–3.2.4; dose/duration/effect-modification details are custom design; M08 §8.2.2, M15 §15.3.1; custom application; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is custom design

N09 · Clinical participants/events, denominators and missingness

Required materials and conditions: Randomized, observed and analyzed units and clinical-event units
Conditions for verification: Randomized, observed and analyzed units and clinical-event units requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Preserve the existing ? grade/untested-outcome note for the selected clinical liver outcome and the current MRI report context. Retain gaps in direct cirrhosis/hospitalization/death material, definitions, effects, denominators and duration. Do not substitute MRI/weight/liver-enzyme measures, values, support or safety for direct clinical effects or create new intake/treatment guidance.
Why this condition is needed: Distinguish Randomized, observed and analyzed units and clinical-event units to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is custom design; M08 §8.2.2, M15 §15.3.1; custom application; M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linkage is a custom application

N10 · Original allocation/blinding and clinical adjudication

Required materials and conditions: Allocation, measurement and analysis procedures in direct clinical trials
Conditions for verification: Allocation, measurement and analysis procedures in direct clinical trials requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Preserve the existing ? grade/untested-outcome note for the selected clinical liver outcome and the current MRI report context. Retain gaps in direct cirrhosis/hospitalization/death material, definitions, effects, denominators and duration. Do not substitute MRI/weight/liver-enzyme measures, values, support or safety for direct clinical effects or create new intake/treatment guidance.
Why this condition is needed: Distinguish Allocation, measurement and analysis procedures in direct clinical trials to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: M08 §8.1–8.2.3; custom application; M08 Table 8.2.a, M03 §3.2.4; custom application; M08 §8.2.2, M15 §15.3.1; custom application; M04 §4.5–4.6 material-collection/selection principles; separation of access/reading and hyperlink conventions are custom design

N11 · Clinical registration and prespecified plans

Required materials and conditions: Registration/hierarchy, analysis and changes for the selected clinical endpoint
Conditions for verification: Registration/hierarchy, analysis and changes for the selected clinical endpoint requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Preserve the existing ? grade/untested-outcome note for the selected clinical liver outcome and the current MRI report context. Retain gaps in direct cirrhosis/hospitalization/death material, definitions, effects, denominators and duration. Do not substitute MRI/weight/liver-enzyme measures, values, support or safety for direct clinical effects or create new intake/treatment guidance.
Why this condition is needed: Distinguish Registration/hierarchy, analysis and changes for the selected clinical endpoint to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: M08 Table 8.2.a, M04 §4.6.3; custom application; M04 §4.5–4.6 material-collection/selection principles; separation of access/reading and hyperlink conventions are custom design; M04 §4.5, §4.6.3; limits on current material conversion reflect the review scope and custom design

N12 · Weight mediation and direct liver effects

Required materials and conditions: Weight/exposure and original MRI/clinical outcomes
Conditions for verification: Weight/exposure and original MRI/clinical outcomes requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Preserve the existing ? grade/untested-outcome note for the selected clinical liver outcome and the current MRI report context. Retain gaps in direct cirrhosis/hospitalization/death material, definitions, effects, denominators and duration. Do not substitute MRI/weight/liver-enzyme measures, values, support or safety for direct clinical effects or create new intake/treatment guidance.
Why this condition is needed: Distinguish Weight/exposure and original MRI/clinical outcomes to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: M03 §3.2.3, M08 §8.2.2–8.2.3; custom application; M08 §8.2.2, M15 §15.3.1; custom application; M03 §3.2.4; custom extension boundary

N13 · Liver enzymes, nonsignificant secondary outcomes and clinical outcomes

Required materials and conditions: Definitions and results for other measures and disease outcomes
Conditions for verification: Definitions and results for other measures and disease outcomes requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Preserve the existing ? grade/untested-outcome note for the selected clinical liver outcome and the current MRI report context. Retain gaps in direct cirrhosis/hospitalization/death material, definitions, effects, denominators and duration. Do not substitute MRI/weight/liver-enzyme measures, values, support or safety for direct clinical effects or create new intake/treatment guidance.
Why this condition is needed: Distinguish Definitions and results for other measures and disease outcomes to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: M04 §4.6.3, M15 §15.3.1–15.3.3; status separation is custom design; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is custom design; M15 §15.3.1–15.3.3; custom application; M03 §3.2.4; custom extension boundary

N14 · Subsequent exposure and clinical attribution

Required materials and conditions: Actual concurrent exposure/treatment and individual course/events
Conditions for verification: Actual concurrent exposure/treatment and individual course/events requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Preserve the existing ? grade/untested-outcome note for the selected clinical liver outcome and the current MRI report context. Retain gaps in direct cirrhosis/hospitalization/death material, definitions, effects, denominators and duration. Do not substitute MRI/weight/liver-enzyme measures, values, support or safety for direct clinical effects or create new intake/treatment guidance.
Why this condition is needed: Distinguish Actual concurrent exposure/treatment and individual course/events to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: M03 §3.2.3, M08 §8.2.2–8.2.3; custom application; M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptation are custom design; M03 §3.2.1–3.2.4; dose/duration/effect-modification details are custom design

N15 · Funding/products and scope of originals

Required materials and conditions: Original trial support disclosures versus direct clinical material
Conditions for verification: Original trial support disclosures versus direct clinical material requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Preserve the existing ? grade/untested-outcome note for the selected clinical liver outcome and the current MRI report context. Retain gaps in direct cirrhosis/hospitalization/death material, definitions, effects, denominators and duration. Do not substitute MRI/weight/liver-enzyme measures, values, support or safety for direct clinical effects or create new intake/treatment guidance.
Why this condition is needed: Distinguish Original trial support disclosures versus direct clinical material to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: Chamgap independence/attribution conditions. The referenced official method sections do not certify every detail of these items; Data collection/selection principles in M04 §4.5–4.6; Access/reading separation and hyperlink rules are Chamgap design

N16 · Clinical harm and safety material

Required materials and conditions: Definitions, collection and follow-up of harms in direct clinical treatment
Conditions for verification: Definitions, collection and follow-up of harms in direct clinical treatment requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Supplementary
Application exceptions: Preserve the existing ? grade/untested-outcome note for the selected clinical liver outcome and the current MRI report context. Retain gaps in direct cirrhosis/hospitalization/death material, definitions, effects, denominators and duration. Do not substitute MRI/weight/liver-enzyme measures, values, support or safety for direct clinical effects or create new intake/treatment guidance.
Why this condition is needed: Distinguish Definitions, collection and follow-up of harms in direct clinical treatment to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: M19 §19.1.2–19.2.4; detailed distinctions are custom design; M19 §19.1.2–19.2.4; custom application; M19 §19.1.2–19.2.4, M04 §4.6.3; custom application; M19 §19.1.2–19.2.4; custom application; M19 §19.1.2–19.2.4; custom application

N17 · Same trial/periods and clinical replication

Required materials and conditions: Relationships among reports/trials/participants/periods and selected clinical material
Conditions for verification: Relationships among reports/trials/participants/periods and selected clinical material requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Preserve the existing ? grade/untested-outcome note for the selected clinical liver outcome and the current MRI report context. Retain gaps in direct cirrhosis/hospitalization/death material, definitions, effects, denominators and duration. Do not substitute MRI/weight/liver-enzyme measures, values, support or safety for direct clinical effects or create new intake/treatment guidance.
Why this condition is needed: Distinguish Relationships among reports/trials/participants/periods and selected clinical material to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linkage is a custom application; M04 §4.6.1–4.6.2, M15 §15.3.1; custom application; M04 §4.5, §4.6.3; limits on current material conversion reflect the review scope and custom design

N18 · Generalization across disease, products and duration

Required materials and conditions: The selected clinical question versus other populations, exposures and durations
Conditions for verification: The selected clinical question versus other populations, exposures and durations requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Preserve the existing ? grade/untested-outcome note for the selected clinical liver outcome and the current MRI report context. Retain gaps in direct cirrhosis/hospitalization/death material, definitions, effects, denominators and duration. Do not substitute MRI/weight/liver-enzyme measures, values, support or safety for direct clinical effects or create new intake/treatment guidance.
Why this condition is needed: Distinguish The selected clinical question versus other populations, exposures and durations to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: M03 §3.2.1; detailed population conditions are custom design; M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptation are custom design; M03 §3.2.1–3.2.4; dose/duration/effect-modification details are custom design; M03 §3.2.4; custom extension boundary

N19 · Original subclaim ? grade, parent C54 and history

Required materials and conditions: Original subclaim values/absences, parent axes, Korean/English text, dates and corrections
Conditions for verification: Original subclaim values/absences, parent axes, Korean/English text, dates and corrections requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Preserve the existing ? grade/untested-outcome note for the selected clinical liver outcome and the current MRI report context. Retain gaps in direct cirrhosis/hospitalization/death material, definitions, effects, denominators and duration. Do not substitute MRI/weight/liver-enzyme measures, values, support or safety for direct clinical effects or create new intake/treatment guidance.
Why this condition is needed: Distinguish Original subclaim values/absences, parent axes, Korean/English text, dates and corrections to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design; M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are internally designed

N20 · Summary/bibliography and gaps in direct clinical material

Required materials and conditions: Actual reading/URLs for each material and selected clinical material
Conditions for verification: Actual reading/URLs for each material and selected clinical material requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Preserve the existing ? grade/untested-outcome note for the selected clinical liver outcome and the current MRI report context. Retain gaps in direct cirrhosis/hospitalization/death material, definitions, effects, denominators and duration. Do not substitute MRI/weight/liver-enzyme measures, values, support or safety for direct clinical effects or create new intake/treatment guidance.
Why this condition is needed: Distinguish Actual reading/URLs for each material and selected clinical material to connect materials needed for the selected question with the current materials in this production item.
Referenced methods: M04 §4.5–4.6 material-collection/selection principles; separation of access/reading and hyperlink conventions are custom design; M04 §4.5, §4.6.3; limits on current material conversion reflect the review scope and custom design; M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are custom design

Referenced methods and the sections actually reviewed

M03 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13

Referenced principle: Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

M04 · Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03

Official methodology · §4.5, §4.6.1–4.6.3, MECIR C42

Referenced principle: Distinguish studies from reports and link them; do not omit a study solely because results are unreported.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

M08 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §8.1–8.2.3, Table 8.2.a

Referenced principle: Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

M15 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §15.2.4, §15.3.1–15.3.3

Referenced principle: Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

M19 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §19.1.2, §19.2.1–19.2.4

Referenced principle: Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

What the statuses mean

Met: Status for necessary evidence confirmed after existing content review. No completion is declared in the current presentation.
Partly verified: Some information in the stored summary is linked into the table. External comparison/content review is not complete.
Unverified: The article leaves this unverified, or required material is absent from the current stored summary. This is distinct from zero, absence or safety.
Review incomplete: Existing content review remains incomplete.
Not reported: Not reported within the stored material actually read; not extended to the entire primary paper.
Inaccessible: Means an actual access failure. Access not attempted here is not assigned this state.
Not applicable: Not used as a substitute for an evidence gap.
Conflicting data: Requires an observed disagreement under the same comparison criteria; not automatically judged in this production.
Insufficient evidence for the conditions: Marks a gap in additional material required by the selected conditions; not a new efficacy grade.

Change history

2026-10-12 · Public page/material version 1.0

Public-facing pages and materials were prepared from the existing 20 items. No new clinical search, verification-status change or scoring was performed.

The stored-material review date (Not recorded) and original evidence cut-off (2026-08-26) were retained unchanged.

Researcher downloads

These materials provide the same evidence, scope and verification status as this page.

View all item details

N01 · Selected clinical liver outcome and original values

Current findings: Preserve the existing ? grade for improved clinical liver outcomes and the note that cirrhosis, hospitalization and death were not tested. Parent C54 and the positive MRI result belong to the separate original assessment context.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. The subclaim has no score, status or assessment axes; do not fill them with parent values. Do not create clinical benefit, a null effect, a grade or independent certification. Content review remains incomplete.
Reason for missing information: The subclaim has no score, status or assessment axes; do not fill them with parent values. Do not create clinical benefit, a null effect, a grade or independent certification.
Required materials and conditions: Existing question, grade and note; parent context and absent fields
Materials to obtain first: Selected question, parent assessment and direct clinical material
Further research: Connect the original question to additional materials in proposed update research; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Existing question, grade and note; parent context and absent fields requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Existing question, grade and note; parent context and absent fields to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Preserve the existing ? grade/untested-outcome note for the selected clinical liver outcome and the current MRI report context. Retain gaps in direct cirrhosis/hospitalization/death material, definitions, effects, denominators and duration. Do not substitute MRI/weight/liver-enzyme measures, values, support or safety for direct clinical effects or create new intake/treatment guidance.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are custom design; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is custom design; M04 §4.5, §4.6.3; limits on current material conversion reflect the review scope and custom design

Related sources S01

N02 · Clinical outcomes: definitions and measurement

Current findings: The original note states that this trial did not test cirrhosis, hospitalization or death. Distinguish MRI liver fat and liver enzymes from actual disease outcomes.
Verification status: Unverified
Materials actually read: Summary read; external material unread
Why unverified: Information currently needed is unverified in the preserved summary. Definitions, adjudication/verification, events/denominators, timing and data linkage for direct clinical endpoints are unverified. Untested outcomes must not become zero events or zero effect. Content review remains incomplete.
Reason for missing information: Definitions, adjudication/verification, events/denominators, timing and data linkage for direct clinical endpoints are unverified. Untested outcomes must not become zero events or zero effect.
Required materials and conditions: Definitions and adjudication of original outcomes such as cirrhosis, hospitalization and death
Materials to obtain first: Clinical endpoint definitions/adjudication and direct event/observation data
Further research: Proposed research distinguishing imaging/laboratory measures from clinical outcomes; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Definitions and adjudication of original outcomes such as cirrhosis, hospitalization and death requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Definitions and adjudication of original outcomes such as cirrhosis, hospitalization and death to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Preserve the existing ? grade/untested-outcome note for the selected clinical liver outcome and the current MRI report context. Retain gaps in direct cirrhosis/hospitalization/death material, definitions, effects, denominators and duration. Do not substitute MRI/weight/liver-enzyme measures, values, support or safety for direct clinical effects or create new intake/treatment guidance.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is custom design; M08 Table 8.2.a, M03 §3.2.4; custom application; M03 §3.2.4; custom extension boundary; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is custom design

Related sources S01

N03 · Participants, disease and risk scope

Current findings: The current direct bibliography concerns an MRI crossover trial in 41 people with nonalcoholic fatty liver disease. Do not transfer them into a verified direct population for the selected clinical outcome.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Clinical disease stage, baseline risk, eligibility, populations by group and clinical-event denominators/missingness are unverified. Do not transfer an effect to every liver disease or population. Content review remains incomplete.
Reason for missing information: Clinical disease stage, baseline risk, eligibility, populations by group and clinical-event denominators/missingness are unverified. Do not transfer an effect to every liver disease or population.
Required materials and conditions: Original MRI participants and the population analyzed for clinical outcomes
Materials to obtain first: Disease-specific recruitment/baseline data and direct analysis/observation populations
Further research: Proposed research on disease/population and the applicability of clinical effects; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original MRI participants and the population analyzed for clinical outcomes requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Original MRI participants and the population analyzed for clinical outcomes to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Preserve the existing ? grade/untested-outcome note for the selected clinical liver outcome and the current MRI report context. Retain gaps in direct cirrhosis/hospitalization/death material, definitions, effects, denominators and duration. Do not substitute MRI/weight/liver-enzyme measures, values, support or safety for direct clinical effects or create new intake/treatment guidance.
Referenced methods: M03 §3.2.1; detailed population conditions are custom design; M03 §3.2.1–3.2.4; dose/duration/effect-modification details are custom design; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is custom design

Related sources S01

N04 · Quercetin and direct clinical intervention

Current findings: 500 mg/day, 12 weeks and placebo crossover are exposure/comparison conditions of the original MRI trial. Do not describe them as a dose or method with verified clinical liver benefit.
Verification status: Unverified
Materials actually read: Summary read; external material unread
Why unverified: Information currently needed is unverified in the preserved summary. Product/composition, dose/duration, intervention/control, actual exposure, adherence and subsequent treatment in direct clinical trials are unverified. Do not create new dosing or treatment guidance. Content review remains incomplete.
Reason for missing information: Product/composition, dose/duration, intervention/control, actual exposure, adherence and subsequent treatment in direct clinical trials are unverified. Do not create new dosing or treatment guidance.
Required materials and conditions: Formulation, dose, strategy and actual clinical comparison
Materials to obtain first: Product/intervention/control and actual exposure data for each clinical trial
Further research: Proposed research on formulation/strategy and attribution to the clinical question; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Formulation, dose, strategy and actual clinical comparison requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Formulation, dose, strategy and actual clinical comparison to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Preserve the existing ? grade/untested-outcome note for the selected clinical liver outcome and the current MRI report context. Retain gaps in direct cirrhosis/hospitalization/death material, definitions, effects, denominators and duration. Do not substitute MRI/weight/liver-enzyme measures, values, support or safety for direct clinical effects or create new intake/treatment guidance.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labels and checking adaptations are internally designed; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application; M03 §3.2.1–3.2.4; dose, duration and effect-modification details are internally designed

Related sources S01

N05 · Direct bibliography, registration and report relationships

Current findings: The existing evidence and citation lists contain only the Li 2024 MRI trial. This preserved review summary links no direct report of clinical cirrhosis, hospitalization or death.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Direct clinical originals, trial/registration, plans/follow-up material, identity and scope are unverified or unread. Do not invent reports/URLs or new external reading. Content review remains incomplete.
Reason for missing information: Direct clinical originals, trial/registration, plans/follow-up material, identity and scope are unverified or unread. Do not invent reports/URLs or new external reading.
Required materials and conditions: Direct original reports, registration and correspondence for the selected clinical question
Materials to obtain first: Direct bibliography, registration and original reports for clinical endpoints
Further research: Proposed research linking the original text/assessment with direct reports; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Direct original reports, registration and correspondence for the selected clinical question requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Direct original reports, registration and correspondence for the selected clinical question to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Preserve the existing ? grade/untested-outcome note for the selected clinical liver outcome and the current MRI report context. Retain gaps in direct cirrhosis/hospitalization/death material, definitions, effects, denominators and duration. Do not substitute MRI/weight/liver-enzyme measures, values, support or safety for direct clinical effects or create new intake/treatment guidance.
Referenced methods: M04 §4.5–4.6 material-collection/selection principles; separation of access/reading and hyperlink conventions are custom design; M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linkage is a custom application; M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are custom design

Related sources S01

N06 · Original MRI values and clinical effects

Current findings: MRI 11.5%±6.4→9.6%±5.8, placebo change −0.1%±2.6, P=.013 and adjusted P=.028 are MRI results. They are not estimates for cirrhosis, hospitalization or death.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Imaging/disease correspondence by person and timepoint and direct clinical material are unverified. Do not calculate clinical events, effects or CIs from MRI changes. Content review remains incomplete.
Reason for missing information: Imaging/disease correspondence by person and timepoint and direct clinical material are unverified. Do not calculate clinical events, effects or CIs from MRI changes.
Required materials and conditions: Surrogate comparisons/timing and their relationship to clinical outcomes
Materials to obtain first: Person-level timing and outcome correspondence between MRI and clinical events
Further research: Proposed research distinguishing surrogate results from actual disease outcomes; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Surrogate comparisons/timing and their relationship to clinical outcomes requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Surrogate comparisons/timing and their relationship to clinical outcomes to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Preserve the existing ? grade/untested-outcome note for the selected clinical liver outcome and the current MRI report context. Retain gaps in direct cirrhosis/hospitalization/death material, definitions, effects, denominators and duration. Do not substitute MRI/weight/liver-enzyme measures, values, support or safety for direct clinical effects or create new intake/treatment guidance.
Referenced methods: M03 §3.2.4; custom extension boundary; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is custom design; M04 §4.6.3, M15 §15.3.1–15.3.3; status separation is custom design; M15 §15.3.1–15.3.3; custom application

Related sources S01

N07 · Between-group clinical effects, CIs and thresholds

Current findings: The original positive MRI result, absent CI in the abstract/public table and undeclared minimum MRI threshold are not verified values or an analysis specification for a clinical effect.
Verification status: Unverified
Materials actually read: Summary read; external material unread
Why unverified: Information currently needed is unverified in the preserved summary. Clinical-event values by group, effects/CIs/P values, models, prespecified important differences and power are unverified. Do not create a treatment effect, null effect, CI or threshold. Content review remains incomplete.
Reason for missing information: Clinical-event values by group, effects/CIs/P values, models, prespecified important differences and power are unverified. Do not create a treatment effect, null effect, CI or threshold.
Required materials and conditions: Direct clinical effect/precision and prespecified important difference
Materials to obtain first: Original clinical analyses, events/estimates/CIs and important-difference/power material
Further research: Proposed research distinguishing clinical uncertainty from clinical meaning; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Direct clinical effect/precision and prespecified important difference requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Direct clinical effect/precision and prespecified important difference to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Preserve the existing ? grade/untested-outcome note for the selected clinical liver outcome and the current MRI report context. Retain gaps in direct cirrhosis/hospitalization/death material, definitions, effects, denominators and duration. Do not substitute MRI/weight/liver-enzyme measures, values, support or safety for direct clinical effects or create new intake/treatment guidance.
Referenced methods: M15 §15.3.1–15.3.3; custom application; M08 Table 8.2.a, M04 §4.6.3; custom application; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is custom design

Related sources S01

N08 · Clinical timing and long-term follow-up

Current findings: The 12-week MRI period and crossover after a four-week washout are not a verified assessment period for clinical cirrhosis, hospitalization or death.
Verification status: Unverified
Materials actually read: Summary read; external material unread
Why unverified: Information currently needed is unverified in the preserved summary. Assessment windows, occurrence/recurrence, long-term follow-up/censoring, discontinuation/death and competing events for direct clinical outcomes are unverified. Do not newly calculate total duration or event totals. Content review remains incomplete.
Reason for missing information: Assessment windows, occurrence/recurrence, long-term follow-up/censoring, discontinuation/death and competing events for direct clinical outcomes are unverified. Do not newly calculate total duration or event totals.
Required materials and conditions: Specifications for event occurrence, exposure, follow-up and censoring
Materials to obtain first: Long-term clinical follow-up, timing/censoring and event/exposure data
Further research: Proposed follow-up research distinguishing duration from disease outcomes; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Specifications for event occurrence, exposure, follow-up and censoring requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Specifications for event occurrence, exposure, follow-up and censoring to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Preserve the existing ? grade/untested-outcome note for the selected clinical liver outcome and the current MRI report context. Retain gaps in direct cirrhosis/hospitalization/death material, definitions, effects, denominators and duration. Do not substitute MRI/weight/liver-enzyme measures, values, support or safety for direct clinical effects or create new intake/treatment guidance.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is custom design; M03 §3.2.1–3.2.4; dose/duration/effect-modification details are custom design; M08 §8.2.2, M15 §15.3.1; custom application; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is custom design

Related sources S01

N09 · Clinical participants/events, denominators and missingness

Current findings: 41 randomized and 36 completed are data from the MRI crossover trial.
Verification status: Unverified
Materials actually read: Summary read; external material unread
Why unverified: Information currently needed is unverified in the preserved summary. Groups/denominators, people/recurrent events, exclusion, missingness, withdrawal/censoring, analysis and missing-data models for each direct clinical endpoint are unverified. Do not automatically reuse MRI denominators. Content review remains incomplete.
Reason for missing information: Groups/denominators, people/recurrent events, exclusion, missingness, withdrawal/censoring, analysis and missing-data models for each direct clinical endpoint are unverified. Do not automatically reuse MRI denominators.
Required materials and conditions: Randomized, observed and analyzed units and clinical-event units
Materials to obtain first: Population flow, events/denominators and missingness/model material for each clinical endpoint
Further research: Proposed research on population/event units and missing-data assumptions; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Randomized, observed and analyzed units and clinical-event units requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Randomized, observed and analyzed units and clinical-event units to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Preserve the existing ? grade/untested-outcome note for the selected clinical liver outcome and the current MRI report context. Retain gaps in direct cirrhosis/hospitalization/death material, definitions, effects, denominators and duration. Do not substitute MRI/weight/liver-enzyme measures, values, support or safety for direct clinical effects or create new intake/treatment guidance.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is custom design; M08 §8.2.2, M15 §15.3.1; custom application; M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linkage is a custom application

Related sources S01

N10 · Original allocation/blinding and clinical adjudication

Current findings: The original double-blind MRI crossover design description belongs to the parent trial context.
Verification status: Unverified
Materials actually read: Summary read; external material unread
Why unverified: Information currently needed is unverified in the preserved summary. Direct allocation units/sequences, generation/concealment, clinical adjudication/analysis blinding, measurement and models for clinical effects are unverified. Do not inherit original B1 or ITT as a new clinical review. Content review remains incomplete.
Reason for missing information: Direct allocation units/sequences, generation/concealment, clinical adjudication/analysis blinding, measurement and models for clinical effects are unverified. Do not inherit original B1 or ITT as a new clinical review.
Required materials and conditions: Allocation, measurement and analysis procedures in direct clinical trials
Materials to obtain first: Direct clinical allocation, adjudication/measurement and analysis records
Further research: Proposed research on procedures and clinically observed outcomes; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Allocation, measurement and analysis procedures in direct clinical trials requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Allocation, measurement and analysis procedures in direct clinical trials to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Preserve the existing ? grade/untested-outcome note for the selected clinical liver outcome and the current MRI report context. Retain gaps in direct cirrhosis/hospitalization/death material, definitions, effects, denominators and duration. Do not substitute MRI/weight/liver-enzyme measures, values, support or safety for direct clinical effects or create new intake/treatment guidance.
Referenced methods: M08 §8.1–8.2.3; custom application; M08 Table 8.2.a, M03 §3.2.4; custom application; M08 §8.2.2, M15 §15.3.1; custom application; M04 §4.5–4.6 material-collection/selection principles; separation of access/reading and hyperlink conventions are custom design

Related sources S01

N11 · Clinical registration and prespecified plans

Current findings: ChiCTR2100047904 and the primary MRI endpoint description are the preserved identity and plan of the original MRI trial. Do not promote clinical endpoints to prespecified, verified outcomes.
Verification status: Unverified
Materials actually read: Summary read; external material unread
Why unverified: Information currently needed is unverified in the preserved summary. Original clinical plans/registration history, endpoint hierarchy/multiplicity, SAP, follow-up/changes and report correspondence are unread. Content review remains incomplete.
Reason for missing information: Original clinical plans/registration history, endpoint hierarchy/multiplicity, SAP, follow-up/changes and report correspondence are unread.
Required materials and conditions: Registration/hierarchy, analysis and changes for the selected clinical endpoint
Materials to obtain first: Direct clinical registration, protocol/SAP and follow-up/change material
Further research: Proposed research linking prespecified plans with clinical reports; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Registration/hierarchy, analysis and changes for the selected clinical endpoint requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Registration/hierarchy, analysis and changes for the selected clinical endpoint to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Preserve the existing ? grade/untested-outcome note for the selected clinical liver outcome and the current MRI report context. Retain gaps in direct cirrhosis/hospitalization/death material, definitions, effects, denominators and duration. Do not substitute MRI/weight/liver-enzyme measures, values, support or safety for direct clinical effects or create new intake/treatment guidance.
Referenced methods: M08 Table 8.2.a, M04 §4.6.3; custom application; M04 §4.5–4.6 material-collection/selection principles; separation of access/reading and hyperlink conventions are custom design; M04 §4.5, §4.6.3; limits on current material conversion reflect the review scope and custom design

Related sources S01

N12 · Weight mediation and direct liver effects

Current findings: Preserve the original weight description: −1.5±2.6 kg versus −0.2±1.8 kg, correlation with MRI reduction and an unseparated direct liver effect. Do not present direct or mediated effects on clinical disease as verified.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Clinical-event correspondence, timing, causal/mediation models and concurrent activity/diet/treatment are unverified. Do not calculate new clinical effects from weight or MRI. Content review remains incomplete.
Reason for missing information: Clinical-event correspondence, timing, causal/mediation models and concurrent activity/diet/treatment are unverified. Do not calculate new clinical effects from weight or MRI.
Required materials and conditions: Weight/exposure and original MRI/clinical outcomes
Materials to obtain first: Timing/correspondence and causal/mediation material for weight/exposure and clinical events
Further research: Proposed research distinguishing exposure/mediation from actual clinical attribution; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Weight/exposure and original MRI/clinical outcomes requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Weight/exposure and original MRI/clinical outcomes to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Preserve the existing ? grade/untested-outcome note for the selected clinical liver outcome and the current MRI report context. Retain gaps in direct cirrhosis/hospitalization/death material, definitions, effects, denominators and duration. Do not substitute MRI/weight/liver-enzyme measures, values, support or safety for direct clinical effects or create new intake/treatment guidance.
Referenced methods: M03 §3.2.3, M08 §8.2.2–8.2.3; custom application; M08 §8.2.2, M15 §15.3.1; custom application; M03 §3.2.4; custom extension boundary

Related sources S01

N13 · Liver enzymes, nonsignificant secondary outcomes and clinical outcomes

Current findings: The original description says other secondary endpoints, including liver enzymes, were nonsignificant. Do not transfer this into verified clinical null effects, an effect of zero or confirmation of MRI benefit.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Plans/timepoints, values/denominators/CIs/models for each measure and correspondence with clinical disease events are unverified. Content review remains incomplete.
Reason for missing information: Plans/timepoints, values/denominators/CIs/models for each measure and correspondence with clinical disease events are unverified.
Required materials and conditions: Definitions and results for other measures and disease outcomes
Materials to obtain first: Definitions, original values/estimates and correspondence for other measures and clinical outcomes
Further research: Proposed research on measure/disease differences and uncertainty; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Definitions and results for other measures and disease outcomes requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Definitions and results for other measures and disease outcomes to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Preserve the existing ? grade/untested-outcome note for the selected clinical liver outcome and the current MRI report context. Retain gaps in direct cirrhosis/hospitalization/death material, definitions, effects, denominators and duration. Do not substitute MRI/weight/liver-enzyme measures, values, support or safety for direct clinical effects or create new intake/treatment guidance.
Referenced methods: M04 §4.6.3, M15 §15.3.1–15.3.3; status separation is custom design; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is custom design; M15 §15.3.1–15.3.3; custom application; M03 §3.2.4; custom extension boundary

Related sources S01

N14 · Subsequent exposure and clinical attribution

Current findings: Retain the original quercetin/placebo trial context.
Verification status: Unverified
Materials actually read: Summary read; external material unread
Why unverified: Information currently needed is unverified in the preserved summary. Diet/activity/weight management, drugs/tests/treatment, products, individual exposure/adherence and subsequent course for clinical disease are unverified. Do not create treatment, weight-management or product guidance. Content review remains incomplete.
Reason for missing information: Diet/activity/weight management, drugs/tests/treatment, products, individual exposure/adherence and subsequent course for clinical disease are unverified. Do not create treatment, weight-management or product guidance.
Required materials and conditions: Actual concurrent exposure/treatment and individual course/events
Materials to obtain first: Concurrent exposure/treatment and actual course data by direct clinical group
Further research: Proposed research on concurrent exposures and attribution of clinical outcomes; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Actual concurrent exposure/treatment and individual course/events requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Actual concurrent exposure/treatment and individual course/events to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Preserve the existing ? grade/untested-outcome note for the selected clinical liver outcome and the current MRI report context. Retain gaps in direct cirrhosis/hospitalization/death material, definitions, effects, denominators and duration. Do not substitute MRI/weight/liver-enzyme measures, values, support or safety for direct clinical effects or create new intake/treatment guidance.
Referenced methods: M03 §3.2.3, M08 §8.2.2–8.2.3; custom application; M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptation are custom design; M03 §3.2.1–3.2.4; dose/duration/effect-modification details are custom design

Related sources S01

N15 · Funding/products and scope of originals

Current findings: The unidentified funding name in public text, undisclosed manufacturer funding/products/analysis, institutional affiliations and no-COI statement are historical descriptions of the original MRI trial.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Full disclosures of funding/products, analysis/writing/publication, company/employee authors, contributions and COI in direct clinical trials are unread. Do not fill absent support or current independence from the original declaration. Content review remains incomplete.
Reason for missing information: Full disclosures of funding/products, analysis/writing/publication, company/employee authors, contributions and COI in direct clinical trials are unread. Do not fill absent support or current independence from the original declaration.
Required materials and conditions: Original trial support disclosures versus direct clinical material
Materials to obtain first: Original funding/support, contribution/employment and COI disclosures for each clinical trial
Further research: Proposed research on support/declarations and actual direct material; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original trial support disclosures versus direct clinical material requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Original trial support disclosures versus direct clinical material to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Preserve the existing ? grade/untested-outcome note for the selected clinical liver outcome and the current MRI report context. Retain gaps in direct cirrhosis/hospitalization/death material, definitions, effects, denominators and duration. Do not substitute MRI/weight/liver-enzyme measures, values, support or safety for direct clinical effects or create new intake/treatment guidance.
Referenced methods: Chamgap independence/attribution conditions. The referenced official method sections do not certify every detail of these items; Data collection/selection principles in M04 §4.5–4.6; Access/reading separation and hyperlink rules are Chamgap design

Related sources S01

N16 · Clinical harm and safety material

Current findings: The original MRI trial description of unreported significant safety-metric differences or related adverse events, 41 participants and limits for rare harms belongs to the parent context.
Verification status: Unverified
Materials actually read: Summary read; external material unread
Why unverified: Information currently needed is unverified in the preserved summary. Harm denominators/events, discontinuation/relatedness, collection/missingness and long-term/vulnerable populations for the clinical population/period are unverified. Do not turn nonreporting into zero harm or treatment safety. Content review remains incomplete.
Reason for missing information: Harm denominators/events, discontinuation/relatedness, collection/missingness and long-term/vulnerable populations for the clinical population/period are unverified. Do not turn nonreporting into zero harm or treatment safety.
Required materials and conditions: Definitions, collection and follow-up of harms in direct clinical treatment
Materials to obtain first: Direct clinical harm collection, group denominators/events, discontinuation and follow-up data
Further research: Proposed research on efficacy and actually observed harms by population; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Definitions, collection and follow-up of harms in direct clinical treatment requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Definitions, collection and follow-up of harms in direct clinical treatment to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Preserve the existing ? grade/untested-outcome note for the selected clinical liver outcome and the current MRI report context. Retain gaps in direct cirrhosis/hospitalization/death material, definitions, effects, denominators and duration. Do not substitute MRI/weight/liver-enzyme measures, values, support or safety for direct clinical effects or create new intake/treatment guidance.
Referenced methods: M19 §19.1.2–19.2.4; detailed distinctions are custom design; M19 §19.1.2–19.2.4; custom application; M19 §19.1.2–19.2.4, M04 §4.6.3; custom application; M19 §19.1.2–19.2.4; custom application; M19 §19.1.2–19.2.4; custom application

Related sources S01

N17 · Same trial/periods and clinical replication

Current findings: Do not count crossover periods/the same people, MRI/weight/liver enzymes, timepoints or sibling sheets from the sole Li 2024 MRI report as new independent trials or participants. Do not invent long-term clinical follow-up reports.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Direct clinical trials/bibliography/registration, unique participants/events, follow-up relationships and independent replication are unverified. Do not inherit original R1/I2 as clinical replication certification. Content review remains incomplete.
Reason for missing information: Direct clinical trials/bibliography/registration, unique participants/events, follow-up relationships and independent replication are unverified. Do not inherit original R1/I2 as clinical replication certification.
Required materials and conditions: Relationships among reports/trials/participants/periods and selected clinical material
Materials to obtain first: Direct clinical report/registration/population/endpoint relationships and separate evidence
Further research: Proposed research distinguishing the same material from separate clinical replication; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Relationships among reports/trials/participants/periods and selected clinical material requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Relationships among reports/trials/participants/periods and selected clinical material to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Preserve the existing ? grade/untested-outcome note for the selected clinical liver outcome and the current MRI report context. Retain gaps in direct cirrhosis/hospitalization/death material, definitions, effects, denominators and duration. Do not substitute MRI/weight/liver-enzyme measures, values, support or safety for direct clinical effects or create new intake/treatment guidance.
Referenced methods: M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linkage is a custom application; M04 §4.6.1–4.6.2, M15 §15.3.1; custom application; M04 §4.5, §4.6.3; limits on current material conversion reflect the review scope and custom design

Related sources S01

N18 · Generalization across disease, products and duration

Current findings: The specific 500 mg/12-week MRI result does not support every polyphenol or improvement in cirrhosis, hospitalization or death.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Direct material for other formulations/doses, disease stages/populations and long-term effects/harms is unverified. Do not create new drug, intake or treatment methods. Content review remains incomplete.
Reason for missing information: Direct material for other formulations/doses, disease stages/populations and long-term effects/harms is unverified. Do not create new drug, intake or treatment methods.
Required materials and conditions: The selected clinical question versus other populations, exposures and durations
Materials to obtain first: Direct clinical and harm material by disease/formulation/duration
Further research: Proposed research on the selected question and other conditions; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: The selected clinical question versus other populations, exposures and durations requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish The selected clinical question versus other populations, exposures and durations to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Preserve the existing ? grade/untested-outcome note for the selected clinical liver outcome and the current MRI report context. Retain gaps in direct cirrhosis/hospitalization/death material, definitions, effects, denominators and duration. Do not substitute MRI/weight/liver-enzyme measures, values, support or safety for direct clinical effects or create new intake/treatment guidance.
Referenced methods: M03 §3.2.1; detailed population conditions are custom design; M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptation are custom design; M03 §3.2.1–3.2.4; dose/duration/effect-modification details are custom design; M03 §3.2.4; custom extension boundary

Related sources S01

N19 · Original subclaim ? grade, parent C54 and history

Current findings: Preserve the subclaim ? grade and untested-outcome note, parent C54/Good, original assessment axes/Korean and English text, 2026-08-26 and empty correction/deliberation records in the full preserved summary.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Do not fill absent subclaim scores/status/axes or the parent’s unrecorded classification information. Do not promote historical cross-validation, abstract/public-table/paper descriptions into current clinical original reading, review or condition fulfillment. Content review remains incomplete.
Reason for missing information: Do not fill absent subclaim scores/status/axes or the parent’s unrecorded classification information. Do not promote historical cross-validation, abstract/public-table/paper descriptions into current clinical original reading, review or condition fulfillment.
Required materials and conditions: Original subclaim values/absences, parent axes, Korean/English text, dates and corrections
Materials to obtain first: Original assessment, correction/change text and user input
Further research: Propose update research on source-material changes and production versions; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original subclaim values/absences, parent axes, Korean/English text, dates and corrections requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Original subclaim values/absences, parent axes, Korean/English text, dates and corrections to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Preserve the existing ? grade/untested-outcome note for the selected clinical liver outcome and the current MRI report context. Retain gaps in direct cirrhosis/hospitalization/death material, definitions, effects, denominators and duration. Do not substitute MRI/weight/liver-enzyme measures, values, support or safety for direct clinical effects or create new intake/treatment guidance.
Referenced methods: M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design; M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are internally designed

Related sources S01

N20 · Summary/bibliography and gaps in direct clinical material

Current findings: Link the preserved summary with Li 2024/PMID 39032786 MRI bibliography/URL. They do not replace direct material or links for clinical disease outcomes.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Direct clinical material and the original MRI paper/registration/protocol/SAP/disclosures are unread; access was not attempted. Do not upgrade current acquisition/reading/review status using original links/identifiers; links/clicks are not checked. Content review remains incomplete.
Reason for missing information: Direct clinical material and the original MRI paper/registration/protocol/SAP/disclosures are unread; access was not attempted. Do not upgrade current acquisition/reading/review status using original links/identifiers; links/clicks are not checked.
Required materials and conditions: Actual reading/URLs for each material and selected clinical material
Materials to obtain first: Direct original clinical reports, registration/plans/disclosures and user input
Further research: Propose scoped update research based on materials actually acquired; no new investigation, calculation or trial is performed now.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Actual reading/URLs for each material and selected clinical material requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
Why this condition is needed: Distinguish Actual reading/URLs for each material and selected clinical material to connect materials needed for the selected question with the current materials in this production item.
Application exceptions: Preserve the existing ? grade/untested-outcome note for the selected clinical liver outcome and the current MRI report context. Retain gaps in direct cirrhosis/hospitalization/death material, definitions, effects, denominators and duration. Do not substitute MRI/weight/liver-enzyme measures, values, support or safety for direct clinical effects or create new intake/treatment guidance.
Referenced methods: M04 §4.5–4.6 material-collection/selection principles; separation of access/reading and hyperlink conventions are custom design; M04 §4.5, §4.6.3; limits on current material conversion reflect the review scope and custom design; M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are custom design

Related sources S01